Wedbush Securities Inc. lowered its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 18.9% in the first quarter, Holdings Channel reports. The fund owned 4,812 shares of the biopharmaceutical company’s stock after selling 1,119 shares during the quarter. Wedbush Securities Inc.’s holdings in Alexion Pharmaceuticals were worth $736,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of ALXN. Wolff Wiese Magana LLC bought a new position in shares of Alexion Pharmaceuticals in the fourth quarter worth about $29,000. Freedman Financial Associates Inc. acquired a new stake in shares of Alexion Pharmaceuticals during the 4th quarter worth approximately $32,000. Eudaimonia Partners LLC grew its position in Alexion Pharmaceuticals by 37.1% in the 3rd quarter. Eudaimonia Partners LLC now owns 288 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 78 shares during the period. Huntington National Bank grew its position in Alexion Pharmaceuticals by 66.9% in the 1st quarter. Huntington National Bank now owns 222 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 89 shares during the period. Finally, Jeppson Wealth Management LLC bought a new position in Alexion Pharmaceuticals during the 3rd quarter valued at $35,000. 87.27% of the stock is owned by hedge funds and other institutional investors.
ALXN stock opened at $170.27 on Tuesday. The company has a quick ratio of 3.26, a current ratio of 3.81 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $37.61 billion, a PE ratio of 39.78, a PEG ratio of 0.75 and a beta of 1.33. Alexion Pharmaceuticals, Inc. has a twelve month low of $94.82 and a twelve month high of $172.08. The stock has a 50-day simple moving average of $157.96 and a two-hundred day simple moving average of $146.14.
ALXN has been the topic of several recent analyst reports. Raymond James cut Alexion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, January 8th. Credit Suisse Group initiated coverage on Alexion Pharmaceuticals in a research note on Monday, April 26th. They set a “neutral” rating and a $190.00 price objective on the stock. Piper Sandler cut Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Thursday, February 4th. Finally, SVB Leerink lifted their target price on Alexion Pharmaceuticals from $156.00 to $173.00 and gave the stock a “market perform” rating in a research note on Monday. Seventeen analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $153.38.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Featured Article: How to calculate the intrinsic value of a stock
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.